Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of December 2021, specifically reporting on a warrant exercise agreement entered into on December 20, 2021. The Company is a biopharmaceutical firm focused on developing treatments for liver diseases, including NASH and liver cancer.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $10.0 million from the cash exercise of warrants.
- Shares Issued: 150,000,000 Ordinary Shares (represented by 5,000,000 ADSs).
- Exercise Price: $2.00 per ADS.
- Placement Agent Fees: 7.0% cash fee on ADSs placed, 1.0% management fee on gross proceeds, and a $75,000 expense allowance.
- Placement Agent Warrants: Warrants to purchase 7.0% of the ADSs placed (350,000 ADSs).
- Private Placement Warrants Issued: New warrants to purchase up to 180,000,000 Ordinary Shares (6,000,000 ADSs) at $2.00 per ADS.
The filing does not provide specific values for revenue, net profit, operating cash flow, margins, total debt, or liquidity ratios for the period.
Material Changes and Use of Proceeds
The primary material change is the capital raise of $10.0 million through the exercise of existing warrants. The Company intends to use the net proceeds for working capital, specifically to fund the launch of a Phase II study in NASH and a Phase III liver cancer study, alongside other general corporate purposes.
Outlook, Risks, and Contingencies
Management Commentary: The transaction supports the Company's clinical development pipeline. The new Private Placement Warrants are immediately exercisable and expire five years following the effectiveness of a resale registration statement.
Risks and Contingencies: The Private Placement Warrants and Wainwright Warrant are unregistered under the Securities Act of 1933 and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption. The transaction relies on the Holder's representation as an accredited investor.
Key Facts for Investor Verification
- Verify the exact net proceeds after deducting the 7.0% placement fee, 1.0% management fee, and $75,000 expense allowance.
- Confirm the dilution impact of issuing 150,000,000 shares plus the potential issuance of 180,000,000 shares via new warrants.
- Review the timeline for the effectiveness of the resale registration statement required for the Private Placement Warrants.
- Assess the Company's current cash runway relative to the costs of the upcoming Phase II NASH and Phase III liver cancer studies.